PT-141 (Bremelanotide) + Egrifta (Tesamorelin): Complete Stack Protocol

What Is PT-141 (Bremelanotide) and How Does It Work?

PT-141, sold under the brand name Vyleesi, is a cyclic heptapeptide that binds melanocortin receptors 3 and 4 (MC3R and MC4R) in the central nervous system. Unlike phosphodiesterase-5 inhibitors, which act peripherally on vascular smooth muscle, bremelanotide drives sexual arousal through hypothalamic and limbic circuits. The FDA approved Vyleesi in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT trials. [1]

Mechanism at the Melanocortin System

The melanocortin system regulates appetite, pigmentation, and sexual function through five receptor subtypes (MC1R through MC5R). MC4R in the paraventricular nucleus of the hypothalamus appears to be the primary mediator of pro-erectile and pro-desire signaling. [2] Bremelanotide's selectivity for MC3R and MC4R over MC1R explains why it produces only mild, transient skin flushing rather than the intense hyperpigmentation seen with older, non-selective analogues like melanotan II.

Clinical Evidence for PT-141 Alone

The two RECONNECT Phase III trials (each N=approximately 600 premenopausal women) demonstrated that 1.75 mg subcutaneous bremelanotide increased satisfying sexual events by approximately 0.5 additional events per month versus placebo (P<0.001) and reduced distress scores significantly. [1] Mean blood pressure rose transiently by 2 to 4 mmHg within 12 hours of dosing, returning to baseline in most participants without intervention. No studies have specifically enrolled men with HSDD, though off-label use in men with psychogenic erectile dysfunction is reported in practitioner-cohort data.

Off-Label Use in Men

Men using compounded bremelanotide typically receive 1.0 to 2.0 mg subcutaneous 45 to 60 minutes before sexual activity. Case-series data suggest subjective improvements in desire and erectile quality, but these reports carry the limitations of uncontrolled, retrospective designs. The FDA has not approved PT-141 for any indication in men. [1]

What Is Egrifta (Tesamorelin) and What Does It Do?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that is 30 amino acids long and conjugated with a trans-2-hexadecanoic acid group to extend its half-life to approximately 26 minutes in plasma versus 7 minutes for native GHRH. [3] The FDA first approved Egrifta in 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy; a supplemental approval for the same indication was issued for Egrifta SV (a new formulation) in 2019. [4]

How Tesamorelin Stimulates GH Release

Tesamorelin binds pituitary GHRH receptors, triggering pulsatile GH secretion in a pattern that mirrors physiological release. Unlike recombinant human growth hormone (rhGH), tesamorelin preserves the natural feedback loop through somatostatin, which reduces the risk of sustained IGF-1 elevation and associated side effects. [3]

Body Composition and Metabolic Effects

In the two Phase III key trials that supported FDA approval (combined N=816 HIV-positive adults), tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by 15.2% from baseline at 26 weeks versus a 1.4% increase in the placebo group (P<0.0001). [5] Trunk fat reductions were accompanied by modest IGF-1 increases averaging 114 ng/mL above baseline. Fasting glucose and HbA1c changes were not statistically significant from placebo in the primary analyses, though the label carries a precaution for glucose monitoring.

Tesamorelin Outside the HIV Setting

Off-label use of tesamorelin for general body composition improvement, cognitive function, and GH optimization in non-HIV adults is increasingly reported in functional medicine and men's health clinics. A 2012 study published in JAMA found that tesamorelin 2 mg daily for 20 weeks reduced VAT by 18% (P<0.0001) and improved lipid parameters in HIV-positive adults, reinforcing the metabolic rationale that practitioners cite when prescribing off-label. [6] Evidence specific to healthy, non-HIV adults remains limited to small open-label studies.

Can You Stack PT-141 and Egrifta Together?

Yes, stacking bremelanotide and tesamorelin is pharmacologically feasible. The two peptides act on completely separate receptor families: melanocortin receptors (PT-141) and GHRH receptors (tesamorelin). There is no identified competitive binding, shared downstream second-messenger pathway that would cause clinically relevant interaction, or overlapping adverse-effect profile that would create additive harm under normal dosing conditions. [2, 3]

Why Practitioners Combine Them

Clinicians at hormone optimization practices typically pair these agents because they address different patient goals simultaneously. Tesamorelin works over weeks to months, gradually shifting body composition toward lower VAT and improved lean mass signaling. PT-141 is on-demand, providing acute central arousal support when needed. The combination allows a patient managing metabolic goals with tesamorelin to also address libido or erectile function concerns without stopping the longer-term protocol.

Evidence Quality for the Stack

No published RCT, Phase II trial, or prospective cohort study has examined bremelanotide and tesamorelin together. The evidence base for stacking rests on:

• Individual FDA approval packages for each drug
• Mechanistic pharmacology (non-overlapping receptors, distinct half-lives)
• Animal data showing no cross-reactivity between melanocortin and GHRH pathways
• Practitioner-reported patient outcomes from hormone clinics (retrospective, uncontrolled)

That is a real limitation. Patients and prescribers should understand that combination safety has not been formally established in humans.

Complete Stack Protocol: Dosing, Timing, and Administration

The protocol below synthesizes FDA label guidance for each agent individually with practitioner-reported dosing practices. It does not represent an FDA-approved regimen. All compounded peptides should come from a licensed 503A or 503B pharmacy.

Tesamorelin Dosing Schedule

• Dose: 2 mg subcutaneous injection, once daily
• Timing: Bedtime administration aligns with physiological GH pulsatility, which peaks during slow-wave sleep. Some practitioners use a morning injection for patients who experience vivid dreams or insomnia with nocturnal dosing.
• Injection site: Abdomen, rotating sites to avoid lipohypertrophy
• Cycle length: FDA trials ran 26 weeks continuously. Off-label practitioners commonly use 12-to-20-week cycles with 4-to-8-week breaks to allow IGF-1 normalization.
• Reconstitution: Egrifta (brand) comes lyophilized; reconstitute with the supplied sterile water per label. Compounded tesamorelin typically arrives in bacteriostatic water.

PT-141 Dosing Schedule

• Dose: 1.75 mg subcutaneous for women (FDA label); 1.0 to 2.0 mg subcutaneous for off-label male use
• Timing: 45 to 60 minutes before anticipated sexual activity; effect onset is 30 to 45 minutes, duration up to 12 hours
• Frequency: Maximum once per 24 hours; most practitioners recommend no more than 8 uses per month based on trial protocols [1]
• Injection site: Abdomen or thigh
• Storage: Refrigerate at 2 to 8 degrees Celsius; protect from light

How to Time Both Peptides on the Same Day

Because tesamorelin is dosed daily at a fixed time and PT-141 is dosed on demand, the simplest approach is to separate injections by at least 60 minutes. A practical schedule:

1. Bedtime tesamorelin at 10:00 PM
2. PT-141 at 9:00 PM (before anticipated activity), then tesamorelin after activity at 10:30 to 11:00 PM
3. On nights with no sexual activity planned, tesamorelin proceeds as normal with no PT-141 dose

Injecting both into the same anatomical site at the same time is not recommended. Different sites, separated timing, reduce the small theoretical risk of altered local absorption kinetics.

Monitoring Parameters

| Parameter | Baseline | 4 Weeks | 12 Weeks | 26 Weeks | |---|---|---|---|---| | IGF-1 | Yes | Optional | Yes | Yes | | Fasting glucose | Yes | Yes | Yes | Yes | | Blood pressure | Yes | Each PT-141 use | Yes | Yes | | Waist circumference | Yes | No | Yes | Yes | | Lipid panel | Yes | No | Yes | Yes | | HbA1c | Yes | No | No | Yes |

The Endocrine Society clinical practice guideline on adult growth hormone deficiency recommends maintaining IGF-1 within the age- and sex-adjusted reference range during GH-axis therapy. [7] The same principle applies to tesamorelin: titrate to IGF-1 within normal limits, not above.

Side Effects: What to Expect From Each Agent and the Combination

PT-141 Side Effects

The RECONNECT trials reported nausea in 40% of bremelanotide-treated women (versus 1% placebo), flushing in 20%, and transient hyperpigmentation of the face, breasts, or gums in 1% with repeated use. [1] Blood pressure elevation of 2 to 4 mmHg systolic occurs within 12 hours of dosing. PT-141 is contraindicated in patients with cardiovascular disease or uncontrolled hypertension.

Tesamorelin Side Effects

In the key trials, the most common adverse events were injection-site reactions (25%), arthralgia (13%), and peripheral edema (9%). [5] IGF-1 elevations above the upper limit of normal occurred in 36% of tesamorelin-treated subjects at some point during 26 weeks of therapy. Glucose impairment is a stated risk on the FDA label; new-onset diabetes was uncommon but did occur in clinical trials.

Additive or Synergistic Risks in the Stack

No mechanistic reason exists to predict additive cardiovascular risk between the two agents. Tesamorelin does not raise blood pressure. PT-141's transient pressor effect is the primary cardiovascular signal, and it is not potentiated by GH-axis stimulation. The combination may carry an additive fluid-retention signal in susceptible individuals: PT-141 has not been reported to cause edema, but tesamorelin-induced GH release promotes sodium and water retention at the kidney level. Patients with pre-existing cardiac or renal disease should have closer monitoring.

Who Should Not Use This Stack

• Anyone with a history of cardiovascular disease, stroke, or uncontrolled hypertension (PT-141 contraindication) [1]
• Patients with active malignancy (GH axis stimulation is contraindicated) [4]
• Pregnant or breastfeeding individuals
• Patients with pre-existing type 2 diabetes requiring close glucose management, without physician co-management of tesamorelin dosing
• Anyone using compounded peptides from a non-FDA-registered pharmacy

How This Stack Compares to Other Sexual Function or GH Stacks

PT-141 vs. PDE5 Inhibitors

Sildenafil (Viagra) and tadalafil (Cialis) act peripherally on vascular smooth muscle through cGMP upregulation. They do not address desire. PT-141 acts centrally and targets libido, not just erection mechanics. Some practitioners combine a low-dose PDE5 inhibitor with PT-141 for men with both desire and vascular erectile dysfunction, though no RCT has examined this triple combination. The FDA label for Vyleesi does not address concomitant PDE5 inhibitor use directly. [1]

Tesamorelin vs. Sermorelin or CJC-1295

Sermorelin is an older GHRH analogue with a shorter active sequence (29 amino acids) and a shorter half-life than tesamorelin. CJC-1295 (with DAC) achieves a multi-day half-life through albumin binding. Tesamorelin's 26-week VAT reduction data remain the strongest body-composition evidence for any GHRH analogue in humans. [5] Practitioners who prefer tesamorelin over sermorelin for this stack specifically cite the VAT evidence and the regulatory history supporting quality-controlled manufacturing standards.

Adding Ipamorelin to the Stack

Some protocols layer ipamorelin, a GH secretagogue (GHRP), onto tesamorelin to achieve additive GH pulse amplitude. Ipamorelin is not FDA-approved for any indication. Adding a third peptide to a two-compound stack increases complexity, interaction uncertainty, and cost without any RCT backing. The HealthRX medical team does not recommend routine triple stacking without specialist supervision and baseline IGF-1 trending.

Practical Considerations: Cost, Access, and Compounding

FDA-Approved Brand vs. Compounded

• Vyleesi (bremelanotide 1.75 mg auto-injector): FDA-approved, available through retail pharmacies with a prescription. Cash price approximately $950 to $1,200 per 4-pack without insurance.
• Egrifta SV (tesamorelin 2 mg): FDA-approved, primarily dispensed through specialty pharmacies. Cash price for a 30-day supply commonly exceeds $4,000.
• Compounded versions: Significantly less expensive (often $150 to $350 per month for tesamorelin, $40 to $80 per vial for PT-141) but are not FDA-approved, are not interchangeable with brand products, and carry variable sterility and potency.

503B outsourcing facilities registered with the FDA operate under cGMP standards and represent a higher-quality option than 503A compounding pharmacies for these peptides, though both remain outside the brand-approval framework. [8]

Prescription Requirements

Both tesamorelin and bremelanotide require a valid prescription in the United States. Neither is a controlled substance, but telehealth prescribing of compounded peptides is subject to evolving DEA and FDA guidance. Patients should confirm that their prescriber is licensed in their state and that the dispensing pharmacy is registered with the FDA.

What the Guidelines Say

The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency in adults states: "We recommend against GH treatment in patients with active malignancy, intracranial hypertension, or proliferative or severe nonproliferative diabetic retinopathy." [7] This guidance extends by clinical reasoning to tesamorelin, though tesamorelin is not recombinant GH.

The International Society for Sexual Medicine (ISSM) guidelines on HSDD note that bremelanotide is "an effective, on-demand pharmacological option for premenopausal women with acquired generalized HSDD, with a number-needed-to-treat of approximately 7 for a minimally important clinical difference in desire." [9]

No professional society guideline currently addresses combining GHRH analogues with melanocortin agonists. The absence of a guideline does not imply safety or efficacy of the combination.

Evidence Gaps and Research Horizon

The most pressing unanswered questions for this stack are:

1. Does concurrent GH-axis stimulation alter melanocortin signaling density or MC4R expression? Animal data show GH and IGF-1 modulate hypothalamic neuropeptide expression, but no data exist for MC3R or MC4R specifically in the context of GHRH analogue use.
2. Does the transient blood pressure effect of PT-141 change in the presence of tesamorelin-induced GH pulses? GH itself can cause mild fluid retention and subtle cardiovascular effects at supraphysiological levels.
3. What are the long-term immunogenicity profiles when both peptides are used together? Tesamorelin generates anti-tesamorelin antibodies in up to 49% of patients by 52 weeks; antibody cross-reactivity with other peptides is uncharacterized. [4]